Stock Events

Stock Events

Annovis Bio 

$1.8600
61
-$0.09-4.62% 19:59 Today
+$0.02+1.08%21:02After hours

Statistics

Day High
1.98
Day Low
1.82
52W High
5.5
52W Low
1.54
Volume
1,166,395
Avg. Volume
1,142,042
Mkt Cap
79.13M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.97
-0.74
-0.5
-0.27
Expected EPS
-0.453333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-28.85MNet Income

Analyst Ratings

12.50Average Price Target
The highest estimate is 17.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANVS. It's not an investment recommendation.
NVIDIA
15
NVDA
Amazon
9
AMZN
Apple
7
AAPL
Tesla
7
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31.91B
Biogen focuses on neurodegenerative diseases, directly competing with Annovis Bio's Alzheimer's and Parkinson's disease treatments.
Lilly(Eli) &
LLY
Mkt Cap1.08T
Eli Lilly has a strong pipeline in Alzheimer's disease treatments, making it a direct competitor to Annovis Bio.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.45B
Acadia Pharmaceuticals targets central nervous system disorders including Parkinson's disease, competing with Annovis Bio.
Anavex Life Sciences
AVXL
Mkt Cap255.77M
Anavex Life Sciences Corp. works on developing treatments for Alzheimer's disease, directly competing with Annovis Bio.
Axsome Therapeutics
AXSM
Mkt Cap12.57B
Axsome Therapeutics develops novel therapies for central nervous system disorders, including Alzheimer's, making it a competitor.
Prothena
PRTA
Mkt Cap497.36M
Prothena Corporation plc focuses on the development of treatments for neurodegenerative diseases, competing in the same space as Annovis Bio.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.76B
Alnylam Pharmaceuticals develops RNAi therapeutics for neurodegenerative diseases, positioning it as a competitor to Annovis Bio.
Ionis Pharmaceuticals
IONS
Mkt Cap13.52B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery for neurodegenerative diseases, making it a competitor.

About

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Show more...
CEO
Dr. Maria L. Maccecchini Ph.D.
Employees
8
Country
United States
ISIN
US03615A1088

Listings

STU
DE
07X.STU
MU
DE
07X.MU
XNYS
US
ANVS
BOATS
BOATS
ANVS.BOATS

0 Comments

Share your thoughts

FAQ

What is Annovis Bio stock price today?▼
The current price of ANVS is $1.86 USD — it has decreased by -4.62% in the past 24 hours. Watch Annovis Bio stock price performance more closely on the chart.
What is Annovis Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Annovis Bio stocks are traded under the ticker ANVS.
Is Annovis Bio stock price growing?▼
ANVS stock has fallen by -3.63% compared to the previous week, the month change is a +8.14% rise, over the last year Annovis Bio has showed a -34.74% decrease.
What is Annovis Bio market cap?▼
Today Annovis Bio has the market capitalization of 79.13M
When is the next Annovis Bio earnings date?▼
Annovis Bio is going to release the next earnings report on August 18, 2026.
What were Annovis Bio earnings last quarter?▼
ANVS earnings for the last quarter are -0.63 USD per share, whereas the estimation was -0.4 USD resulting in a -59.49% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Annovis Bio revenue for the last year?▼
Annovis Bio revenue for the last year amounts to 0 USD.
What is Annovis Bio net income for the last year?▼
ANVS net income for the last year is -28.85M USD.
How many employees does Annovis Bio have?▼
As of July 10, 2026, the company has 8 employees.
In which sector is Annovis Bio located?▼
Annovis Bio operates in the Health & Wellness sector.
When did Annovis Bio complete a stock split?▼
Annovis Bio has not had any recent stock splits.
Where is Annovis Bio headquartered?▼
Annovis Bio is headquartered in Malvern, United States.